The optimal timeframe for donating convalescent plasma for use in COVID-19 immunotherapy, which was given emergency use authorization by the Food and Drug Administration in August 2020, is within 60 days of the onset of symptoms, according to a new study. The research also reveals that the ideal convalescent plasma donor is a recovered COVID-19 patient who is older than 30 and whose illness had been severe.